dacomitinib hydrate
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
EGFR Mutation-positive Inoperable or Reccrent NSCLC
Conditions
EGFR Mutation-positive Inoperable or Reccrent NSCLC
Trial Timeline
Jan 24, 2020 → Apr 25, 2025
NCT ID
NCT04155541About dacomitinib hydrate
dacomitinib hydrate is a pre-clinical stage product being developed by Pfizer for EGFR Mutation-positive Inoperable or Reccrent NSCLC. The current trial status is completed. This product is registered under clinical trial identifier NCT04155541. Target conditions include EGFR Mutation-positive Inoperable or Reccrent NSCLC.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04155541 | Pre-clinical | Completed |
Competing Products
20 competing products in EGFR Mutation-positive Inoperable or Reccrent NSCLC
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YH25448 | Yuhan | Phase 1/2 | 41 |
| YH32364 | Yuhan | Phase 1/2 | 41 |
| Datopotamab deruxtecan | Daiichi Sankyo | Pre-clinical | 23 |
| HER3-DXd | Daiichi Sankyo | Pre-clinical | 23 |
| ASP8273 | Astellas Pharma | Phase 2 | 52 |
| radio-labeled naquotinib + naquotinib | Astellas Pharma | Phase 1 | 33 |
| erlotinib | Astellas Pharma | Phase 1 | 33 |
| ASP8273 Capsules + ASP8273 Capsules A | Astellas Pharma | Phase 2 | 52 |
| famitinib po + HS-10296 po | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| ABT-414 | AbbVie | Pre-clinical | 23 |
| AZD9291 40 mg + AZD9291 80 mg | AstraZeneca | Phase 1 | 33 |
| Osimertinib-based adaptive treatment + Osimertinib 80 MG | AstraZeneca | Phase 2 | 52 |
| AZD9291 + MEDI4736 | AstraZeneca | Phase 3 | 77 |
| EGFR TKIs (gefitinib, erlotinib, afatinib, et al) | AstraZeneca | Pre-clinical | 23 |
| AZD9291 | AstraZeneca | Pre-clinical | 23 |
| Osimertinib | AstraZeneca | Phase 2 | 52 |
| Dasatinib + Osimertinib | AstraZeneca | Phase 1/2 | 41 |
| AZD9291 80mg oral each day | AstraZeneca | Phase 3 | 77 |
| Tremelimumab + Durvalumab | AstraZeneca | Phase 2 | 52 |
| Osimertinib | AstraZeneca | Phase 2 | 52 |